top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

Jeffrey Ives Biography and Net Worth

Director of Cara Therapeutics

Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer's disease, from 2008 until 2013. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001-2007, served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University.

What is Jeffrey L. Ives' net worth?: The estimated net worth of Jeffrey L. Ives is at least $10,943.08 as of July 15th, 2022. Dr. Ives owns 15,476 shares of Cara Therapeutics stock worth more than $10,943 as of April 23rd. This net worth approximation does not reflect any other investments that Dr. Ives may own. Learn More about Jeffrey L. Ives' net worth.
How do I contact Jeffrey L. Ives?: The corporate mailing address for Dr. Ives and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Jeffrey L. Ives' contact information.
Has Jeffrey L. Ives been buying or selling shares of Cara Therapeutics?: Jeffrey L. Ives has not been actively trading shares of Cara Therapeutics during the last ninety days. Most recently, Jeffrey L. Ives sold 3,600 shares of the business's stock in a transaction on Friday, July 15th. The shares were sold at an average price of $9.05, for a transaction totalling $32,580.00. Following the completion of the sale, the director now directly owns 15,476 shares of the company's stock, valued at $140,057.80. Learn More on Jeffrey L. Ives' trading history.
Who are Cara Therapeutics' active insiders?: Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (Pres), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.
Are insiders buying or selling shares of Cara Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 74,015 shares worth more than $85,004.00. The most recent insider tranaction occured on April, 5th when insider Joana Goncalves sold 2,753 shares worth more than $2,284.99. Insiders at Cara Therapeutics own 4.2% of the company. Learn More about insider trades at Cara Therapeutics.
Information on this page was last updated on 4/5/2024.

Jeffrey L. Ives Insider Trading History at Cara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/15/2022	Sell	3,600	$9.05	$32,580.00	15,476
11/12/2021	Sell	8,180	$16.04	$131,207.20
6/1/2020	Sell	1,000	$16.00	$16,000.00	7,000
5/12/2020	Sell	2,500	$16.00	$40,000.00	8,500
4/21/2020	Sell	2,500	$16.00	$40,000.00	8,500
3/4/2020	Sell	2,500	$16.00	$40,000.00	8,500
1/2/2020	Sell	2,500	$16.13	$40,325.00	8,500
12/2/2019	Sell	2,500	$25.83	$64,575.00	8,500
11/1/2019	Sell	2,500	$20.68	$51,700.00	8,500
10/1/2019	Sell	2,500	$18.21	$45,525.00	8,500
9/3/2019	Sell	2,500	$23.31	$58,275.00	8,500
8/1/2019	Sell	2,500	$23.24	$58,100.00	8,500
7/1/2019	Sell	2,500	$21.75	$54,375.00	8,500

Jeffrey L. Ives Buying and Selling Activity at Cara Therapeutics

Cara Therapeutics Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $0.71

$0.70

$0.73

50 Day Range

MA: $0.82

$0.53

$1.05

2 Week Range

Now: $0.71

$0.50

$4.67

Volume

181,919 shs

Average Volume

653,295 shs

Market Capitalization

$38.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7